Your browser doesn't support javascript.
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.
Vuagnat, Perrine; Frelaut, Maxime; Ramtohul, Toulsie; Basse, Clémence; Diakite, Sarah; Noret, Aurélien; Bellesoeur, Audrey; Servois, Vincent; Hequet, Delphine; Laas, Enora; Kirova, Youlia; Cabel, Luc; Pierga, Jean-Yves; Bozec, Laurence; Paoletti, Xavier; Cottu, Paul; Bidard, François-Clément.
  • Vuagnat P; UVSQ, Université Paris-Saclay, Saint Cloud, France.
  • Frelaut M; Department of Medical Oncology, Institut Curie, Paris, France.
  • Ramtohul T; Department of Medical Oncology, Institut Curie, Saint Cloud, France.
  • Basse C; Department of Drug Development and Innovation, Institut Curie, Paris, France.
  • Diakite S; Department of Radiology, Institut Curie, Paris, France.
  • Noret A; Department of Medical Oncology, Institut Curie, Paris, France.
  • Bellesoeur A; Department of Medical Oncology, Institut Curie, Saint Cloud, France.
  • Servois V; Department of Medical Oncology, Institut Curie, Paris, France.
  • Hequet D; Department of Medical Oncology, Institut Curie, Saint Cloud, France.
  • Laas E; Department of Medical Oncology, Institut Curie, Paris, France.
  • Kirova Y; Department of Medical Oncology, Institut Curie, Saint Cloud, France.
  • Cabel L; Department of Medical Oncology, Institut Curie, Paris, France.
  • Pierga JY; Department of Medical Oncology, Institut Curie, Saint Cloud, France.
  • Bozec L; Department of Surgical Oncology, Institut Curie, Paris, France.
  • Paoletti X; Department of Surgical Oncology, Institut Curie, Paris, France.
  • Cottu P; Department of Radiation Oncology, Institut Curie, Paris, France.
  • Bidard FC; Department of Medical Oncology, Institut Curie, Paris, France.
Breast Cancer Res ; 22(1): 55, 2020 05 28.
Article in English | MEDLINE | ID: covidwho-381865
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France).

METHODS:

An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities.

RESULTS:

Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death.

CONCLUSIONS:

This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Breast Neoplasms / Coronavirus Infections Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Reviews Topics: Long Covid Limits: Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: English Journal: Breast Cancer Res Journal subject: Neoplasms Year: 2020 Document Type: Article Affiliation country: S13058-020-01293-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Breast Neoplasms / Coronavirus Infections Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Reviews Topics: Long Covid Limits: Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: English Journal: Breast Cancer Res Journal subject: Neoplasms Year: 2020 Document Type: Article Affiliation country: S13058-020-01293-8